Schneider M R, Humm A, Graf A H
Institut für Pharmazie, Universität Regensburg, Federal Republic of Germany.
J Cancer Res Clin Oncol. 1990;116(2):159-67. doi: 10.1007/BF01612671.
For many years, diethylstilbestrol (DES) and its diphosphate (DESPP; Honvan) have been standard therapies for prostatic carcinoma. The effects of DES, its monophosphate (DESP) and of DESPP on the weights of accessory sex organs of mice and rats, and on the experimental Noble Nb-H and Nb-R prostatic carcinomas of the rat were, therefore, compared. In intact mature mice, all three compounds led to a strong and dose-dependent inhibition of seminal vesicle weights and testosterone levels, whereas only a slight antiandrogenic activity in castrated mice was found. In intact rats, DES, DESP and DESPP strongly inhibited accessory sex organ weights and testosterone levels. In castrated rats, however, no antiandrogenic activity was determinable. The prostate carcinoma-inhibiting effects of DES and DESPP were tested in comparison with castration in the transplantable hormone-sensitive Nb-H and Nb-R prostatic carcinoma in rats. Whereas castration caused only a retardation of tumor growth, DES and DESPP (3 x 0.1 mg/kg and 1.0 mg/kg weekly s.c.) led to an almost complete inhibition, which was significantly (P less than 0.01) better than the effect of castration. As the weights of accessory sex organs were identically reduced by either castration or the estrogens, a direct tumor-inhibiting effect of DES and DESPP in addition to their testosterone-lowering activity is obvious. This was proved in an experiment with castrated rats. The only slightly inhibitory activity of castration was strongly potentiated by concomitant administration of DES. Moreover, histological examinations revealed that Nb-H and Nb-R tumors were much more damaged by treatment with DES or DESPP than after castration. Morphometry of the tumors showed that tumor reduction is associated with a decrease in the ratio of the epithelial to the stromal density, i.e. there was an even more pronounced decrease in epithelial cells than that found by merely measuring tumor area. These studies show that the prostate carcinoma-inhibiting effect of DES and DESPP in the Nb model is superior to the effect of castration and that they act directly on the tumor cells used, even in castrated rats.
多年来,己烯雌酚(DES)及其二磷酸盐(DESPP;己烯雌酚二磷酸酯)一直是前列腺癌的标准治疗药物。因此,对DES、其一磷酸盐(DESP)和DESPP对小鼠和大鼠附属性器官重量以及对大鼠实验性诺布尔Nb-H和Nb-R前列腺癌的影响进行了比较。在完整的成熟小鼠中,所有这三种化合物都导致精囊重量和睾酮水平出现强烈的剂量依赖性抑制,而在去势小鼠中仅发现轻微的抗雄激素活性。在完整的大鼠中,DES、DESP和DESPP强烈抑制附属性器官重量和睾酮水平。然而,在去势大鼠中,无法测定到抗雄激素活性。在大鼠可移植的激素敏感性Nb-H和Nb-R前列腺癌中,将DES和DESPP的前列腺癌抑制作用与去势进行了比较。去势仅导致肿瘤生长迟缓,而DES和DESPP(每周皮下注射3次,每次0.1mg/kg和1.0mg/kg)导致几乎完全抑制,这明显(P小于0.01)优于去势的效果。由于去势或雌激素均可使附属性器官重量同等程度降低,因此DES和DESPP除了具有降低睾酮的活性外,还具有直接的肿瘤抑制作用,这一点很明显。这在一项去势大鼠实验中得到了证实。去势的微弱抑制活性因同时给予DES而得到强烈增强。此外,组织学检查显示,与去势后相比,用DES或DESPP治疗后Nb-H和Nb-R肿瘤受到的损伤更大。肿瘤形态计量学显示,肿瘤缩小与上皮与基质密度比值的降低相关,即上皮细胞的减少比仅通过测量肿瘤面积所发现的更为明显。这些研究表明,DES和DESPP在Nb模型中的前列腺癌抑制作用优于去势,并且即使在去势大鼠中,它们也能直接作用于所用的肿瘤细胞。